,21 However, several independent phase 3 clinical trials evaluating subcutaneous injection of an anti-IL-17 antibody (Secukinumab) for chronic noninfectious uveitis involving the intermediate or posterior segment of the eye failed to meet the primary efficacy endpoint which was uveitis recurrence during withdrawal of concomitant standard nonspecific immunosuppressive medication.22 The gene discussed is IL17A; the disease is uveitis.